NCT04340427View on ClinicalTrials.gov

A Study of TQB3455 Tablets in Subjects With Advanced Malignancies

PHASE1UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 10, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

December 31, 2021

Conditions
Advanced Malignancies
Interventions
DRUG

TQB3455

TQB3455 tablets is a small molecule oral drug inhibiting IDH2 mutation.

Trial Locations (1)

Unknown

RECRUITING

Chongqing University Cancer Hospital, Chongqing

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY